HSBC Upgraded Teva Pharmaceutical Industries Ltd (TEVA)


Teva Pharmaceutical Industries Ltd (NYSE:TEVA) was upgraded by equities research analysts at HSBC from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday.

Other analysts have also issued research reports about the company. Morgan Stanley reaffirmed an “overweight” rating and set a $69.00 price objective (down previously from $71.00) on shares of Teva Pharmaceutical Industries in a research report on Tuesday, May 3rd. Mizuho reaffirmed a “buy” rating and set a $75.00 price objective (down previously from $78.00) on shares of Teva Pharmaceutical Industries in a research report on Sunday, May 8th. Zacks Investment Research raised Teva Pharmaceutical Industries from a “sell” rating to a “hold” rating in a research report on Wednesday, June 15th. Goldman Sachs Group Inc. lowered Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating in a research report on Friday. Finally, Citigroup Inc. reaffirmed a “buy” rating and set a $75.00 price objective on shares of Teva Pharmaceutical Industries in a research report on Thursday, April 21st. One analyst has rated the stock with a sell rating, five have issued a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $70.35.




10 Safe Dividend Stocks for the Second Quarter

These stocks have been paying their shareholders for a long time With the U.S. stock market fresh off its first quarterly loss si...